Adaptive Biotechnologies ADPT Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by Adaptive Biotechnologies in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.
The official record: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Adaptive Biotechnologies's long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Adaptive Biotechnologies's long-term debt?
- Adaptive Biotechnologies (ADPT) reported long-term debt of $124.75M in Q1 2026.
- How has Adaptive Biotechnologies's long-term debt changed year-over-year?
- Adaptive Biotechnologies's long-term debt decreased by 5.2% year-over-year, from $131.55M to $124.75M.
- What is the long-term trend for Adaptive Biotechnologies's long-term debt?
- Over 3 years (2022 to 2025), Adaptive Biotechnologies's long-term debt has grown at a 0.3% compound annual growth rate (CAGR), from $125.36M to $126.57M.
- What does long-term debt mean?
- Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.